XML 40 R30.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Reporting
The following table presents selected financial information about the Company's single operating segment for the three months ended March 31, 2026 and 2025 (in thousands):
Three Months Ended
March 31,
20262025
Program-specific expenses:
Ulixacaltamide$19,103 $23,513 
Vormatrigine20,494 13,733 
Relutrigine12,854 5,377 
Elsunersen3,197 761 
Other early stage assets3,242 1,105 
Personnel-related expenses17,730 13,030 
Stock-based compensation expense17,112 8,786 
Depreciation expense39 47 
Other segment expenses(a)
12,089 8,376 
Other income, net13,299 5,432 
Consolidated net loss$(92,561)$(69,296)
(a) Other segment expenses includes research and development and general and administrative costs not attributable to a specific program.